Responses
Spondyloarthritis
Original research
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
Compose a Response to This Article
Other responses
No responses have been published for this article.